Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer - Oliver Sartor

Neal Shore and Oliver Sartor cover the topic of racial disparities in prostate cancer and the use of immunotherapy particularly sipuleucel-T in the African American community.  Oliver does a deep dive into the double-blind, placebo-controlled, multicenter trial, Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study, involving 512 men with metastatic castration-resistant prostate cancer, with overall survival as the primary end point. 


A. Oliver Sartor, MD, is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center and the Laborde Professor for Cancer Research, with appointments in both the Medicine and Urology Departments.

Neal Shore, MD, FACS Board Certified Urologist, Medical Director of the Carolina Urologic Research Center, Atlantic Urology Clinics


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.